UK

Lecanemab
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #UK

UK regulator rules benefits of lecanemab do not justify the cost

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing… Read More

#News #Regulatory #Trending News

UK visa application
#Cancer Research UK #Life sciences #Politics #UK #UK government

Strict UK immigration rules hold back cancer research

The UK immigration system is making it much harder for the country’s research institutions to compete for international talent, says Cancer Research UK (CRUK). With their annual visa costs projected to rise by 44% in a single year, the organisation is calling on the new UK… Read More

#News #Trending News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Drug discovery #Japan #UK

UK-Japan partnership to tackle antimicrobial resistance

Two experts in infectious disease have been selected to be policy fellows as part of a wider Japan-UK collaboration to tackle the growing crisis of antimicrobial resistance (AMR). AMR is a major threat to global health and was responsible for 1.27 million deaths in 2019 alone. Read More

#News

UK vector
#Brexit #Clinical trials #Drug discovery #Ireland #UK

Biogen’s vision for UK & Ireland  

DDW Editor Reece Armstrong speaks to Kylie Bromley, General Manager and Managing Director of Biogen UK & Ireland, about her career within the life sciences industry and the challenges of navigating a large pharma company within the UK and Ireland.   RA: Could you tell us about your career leading… Read More

#Exclusive Content

#Biotech hubs #Drug discovery #Drug discovery hotspots #Life sciences #Precision medicine #UK

Whitepaper: Precision medicine and the role of ecosystems

A new whitepaper is now available to download for free from Bruntwood SciTech. This whitepaper, Fuelling the future: Precision medicine innovation and the role of ecosystems, examines how the future of drug discovery and precision medicine can be enhanced by life science ecosystems such as those created by the UK’s… Read More

#News

Whitepaper: Fuelling the future: Precision medicine innovation and the role of ecosystems
#Biotech hubs #Drug discovery #Drug discovery hotspots #Life sciences #Precision medicine #UK

Fuelling the future: Precision medicine innovation and the role of ecosystems

This whitepaper, Fuelling the future: Precision medicine innovation and the role of ecosystems, examines how the future of drug discovery and precision medicine can be enhanced by life science ecosystems such as those created by the UK’s leading property developer to the science and technology sectors, Bruntwood SciTech. In the whitepaper,… Read More

#Resources

Polling station sign
#Association of the British Pharmaceutical Industry #Drug discovery #Medicines Discovery Catapult #UK #UK government

UK 2024 election: A vote for drug discovery

By DDW Editor Reece Armstrong The upcoming general election in the UK has placed the priorities of the country into the spotlight and the drug discovery sector should in no way be forgotten. Economic uncertainty, challenging global conditions and a healthcare system facing serious pressures, means that whatever government takes the… Read More

#Exclusive Content #Opinion

#Biotech #Drug discovery #Funding #Investment #UK

Early-stage biotech investment: where are we? 

Yogan A Patel, Partner at MHA and Head of MHA’s Pharma, Life Science and Med-Tech sector group examines the investment landscape for early-stage biotech companies in the UK and further afield.   It is well recognised by both investors and government that the UK has huge strengths in biotechnology. Investment… Read More

#Exclusive Content

Research laboratory
#Discovery Park #Lab space #UK

New lab space for early-stage life science businesses

Discovery Park has opened CoLab, a new shared lab facility in the UK. In partnership with Canterbury Christ Church University, CoLab has been designed for early-stage life science businesses, providing flexible bench space in a coworking environment. Dr Cornelia Wilson, Senior Lecturer and Academic Laboratory Director… Read More

#News

#Biomanufacturing #HUB Organoids #Molecular Devices #Organoids #UK #Wales

UK facility to manufacture organoids for drug discovery

A new facility has opened in Cardiff, UK designed to manufacture patient-derived organoids (PDOs) at scale for use in drug discovery and development. The multi-million-pound facility was custom-built by Molecular Devices to house its bioprocess workflow and bioreactor technology Mary Duseau, President of Molecular… Read More

#News

Alderley Park
#Alderley Park #Life sciences #Start-ups #UK

Life sciences accelerator launches to bolster UK innovation

A new accelerator programme at Alderley Park has been launched to support innovation and growth in the region. Bruntwood SciTech’s Life Science Accelerator programme has been designed to cater to the unique needs of early-stage life science companies from across the UK, offering comprehensive support and… Read More

#News #Start-up Zone

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

Gilead Sciences, Oxford facility
#Acute inflammatory conditions #Gilead Sciences #MiroBio #Research and development #UK

Gilead Sciences opens first research centre outside US

Gilead Sciences has opened a new research site at the Business Park in Oxford, UK. With capacity for up to 60 research scientists and employees, the company says the site will play a role in helping to drive innovation in the UK life sciences sector, with… Read More

#News

#BioIndustry Association #Biotech #Investment #Market reporting #UK

Buoyant UK biotech sector secures £1.8bn investment in 2023

The UK’s life sciences and biotech sector showed resilience in 2023, securing £1.8 ($2.2) billion in equity investment despite a challenging global economic climate, according to a report by the UK BioIndustry Association (BIA). This follows another BIA report in January 2024, which showed that the UK is a global… Read More

#Business & Investment #News

UK
#Advanced Therapies #BioIndustry Association #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

UK maintains dominant global position in cell and gene therapy

The UK is cementing its position as a global leader in cell and gene therapy (CGT), according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline. The report reveals a robust sector with significant investment, the highest number of… Read More

#News #Trending News